The Committee for Medicinal Products for Human Use (CHMP) of the European Mediciens Agency have recommend Merck’s RECARBRIO (imipenem, cilastatin, and relebactam) for approval by the European Commission.
If the EUC decides to take the committee’s encouraging opinion on board, it will grant the use of centralised marketing to RECARBRIO in European Economic Areas including Norway, Iceland and Liechtenstein, in addition to twenty-eight different countries within the EU.
“RECARBRIO has been recommended to the European Commission“
Senior Vice President of infectious diseases and vaccines at Merck Research Laboratories, Dr. Nicholas Kartsonis, stated: “Merck remains focused on developing new antibacterial medicines that provide meaningful benefit to patients fighting serious bacterial infections. The CHMP positive opinion marks an important milestone as we seek to provide European medical professionals an additional option for critically ill patients with Gram negative bacterial infections.”